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Abstract
Background: Although the large majority of persons with diabetes and other non-communicable diseases (NCDs) lives and
dies in low- and middle-income countries, the prevention and treatment of diabetes and other NCDs is widely neglected in
these areas. A contributing reason may be that, unlike the impacts of acute and communicable diseases, the demands on
resources imposed by diabetes is not superficially obvious, and studies capable of detecting these impacts have not be
done.
Methods: To ascertain recent use of medical services and medicines and other information about the impact of ill-health,
we in 2008–2009 conducted structured, personal interviews with 1,780 persons with diagnosed diabetes (DMs) and 1,770
matched comparison subjects (MCs) without diabetes in Cameroon, Mali, Tanzania and South Africa. We sampled DMs from
diabetes registries and, in Cameroon and South Africa, from attendees at outpatient diabetes clinics. To recruit MCs, we
asked subjects with diabetes to identify five persons living nearest to them who were of the same sex and approximate age.
We estimated diabetes impact on medical services use by calculating ratios and differences between DMs and MCs, testing
for statistical significance using two-stage multivariable hurdle models.
Findings: DMs consumed 12.95 times more days of inpatient treatment, 7.54 times more outpatient visits, and 5.61 times
more medications than MCs (all p,0.001). DMs used an estimated 3.44 inpatient days per person per year, made 10.72
outpatient visits per person per year (excluding traditional healers), and were taking an average of 2.49 prescribed
medicines when interviewed.
Conclusions: In Sub-Saharan Africa, the relative incremental use of medical care and medicines associated with diagnosed
diabetes is much greater than in industrialized countries and in China. Published calculations of the health-system impact of
diabetes in Africa are dramatic underestimates. Although non-communicable diseases like diabetes are commonly thought
to be minor problems for health systems and patients in Africa, our data demonstrate the opposite.
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Background
Non-communicable diseases (NCDs) account for the majority of
disability and premature death in nearly all of the world’s
countries. [1] Diabetes mellitus (DM) is an NCD of particular
interest because untreated DM causes a wide range of other
NCDs, including stroke, heart attack, renal disease, neuropathy,
peripheral artery disease, lower-limb amputation and visual
impairment. In 2011, DM accounted for an estimated 4.6 million
deaths worldwide, more than HIV and malaria combined, and
consumed at least 465 billion current U.S. dollars (USD) for its
treatment. [2,3] In most of the world, type 2 diabetes, the
overwhelmingly predominant form, occurs in people on average
ten years sooner and at a lower body mass index (BMI) than in
populations of European heritage, [4,5] and is linked to family and
individual histories of famine [6–8] as well as to genetic
inheritance, increased life expectancy, current diet, physical
inactivity, [9] stress, [10] and social inequality. [11] Three-
quarters of persons with diabetes live in low- and middle-income
countries (LMICs) [2].
Little information is available for LMICs on the availability, use
of, cost, and quality of medical care for diabetes. A recently
published study covering 12 regions in China reported that, after
direct adjustment for age, sex, and urban/rural location,
individuals with diabetes received 1.93 times more days of
inpatient treatment, 2.40 times more outpatient visits, and 3.35
times more medications than people with normal glucose
tolerance. [12] Expenditures for medical care, adjusted for age
and sex, were 3.38 times higher among Chinese with diabetes than
among Chinese with normal glucose tolerance [12].
Data regarding resource utilization for diabetes care in sub-
Saharan Africa are particularly scarce and difficult to generalize,
although they all indicate that the diabetes-caused use of medical
services and medications is substantial. Chale et al. interviewed
464 patients with diabetes at Muhimbili Medical Center in Dar es
Salaam, Tanzania in 1989–90 and found that insulin and oral
medicines accounted for nearly all their costs of medical care, in
part because the salaries of physicians and nurses at that time were
extremely low. [13] Despite the low salaries, however, annual per-
patient expenditures for diabetes treatment exceeded Tanzania’s
1989 national income per capita, exceeded per capita spending on
health by nearly 20-fold, [14] and accounted for 30.8% of total
expenditures by the hospitals outpatient department. [13] Among
hospital-using urban patients in Cameroon in 2001, Nkegoum
calculated that direct medical care expenditures to treat diabetes
totaled USD 489 per patient per year. Hospital admissions
accounted for 56% of expenditures, followed by glucose lowering
medicines (33.5%), laboratory tests (5.5%), and consultation fees
(4.5%). [15] The International Diabetes Management Practices
study (IDMPS) recruited a stratified random sample of physicians
experienced in insulin therapy from various continents including
one Sub-Saharan African country, the Republic of South Africa,
in 2006–2007. Mean annual general practitioner visits in South
Africa were 3.6 (4.8) per patient, mean number of hospitalizations
per annum was 0.3 (1.2) and the number of emergency room visits
was 0.1 (0.5). Micro- and macro-vascular complications as well as
level of glycaemic control were positively correlated to hospital-
ization [16].
To obtain more complete and generalizable data for Sub-
Saharan Africa, including good estimates of the diabetes to non-
diabetes expenditure ratio, R, we decided to estimate the impact,
cost, and availability of medical care for diabetes using identical,
comparator-controlled methods in several Sub-Saharan countries
simultaneously. In this paper we report the estimates of the use of
medical services and medicines caused by diabetes.
Methods
Ethics Statement
In Mali approval was given by the Faculty of Medicine and
Pharmacy and Dentistry, Research Ethics Committee of the
University of Bamako; in Tanzania this was given by the Medical
Research Coordinating Committee of the Ministry of Health and
in South Africa by the Research Ethics Committee, Faculty of
Health Sciences at the University of Pretoria. Patients gave written
informed consent and the research was conducted in accordance
with the declaration of Helsinki.
Site and Sample Selection
In 2008–2009, Study teams from four Sub-Saharan African
countries–Cameroon, Mali, Tanzania, and South Africa–partici-
pated in the study. We agreed upon a target sample size of 500
cases and 500 controls per country to provide 90% power to detect
a 5 percentage point difference in rates and proportions between
cases and controls in each country. Principal investigators (PIs)
selected sampling locations and sampling sources within their
countries based on representativeness and feasibility. In Camer-
oon, cases were identified and recruited consecutively from
outpatient diabetes clinics at three hospitals in Yaoundé, the
country’s capital and largest city (specifically, Yaoundé Central
Hospital, the national referral and teaching hospital, where 80% of
cases were obtained, the District Hospital of Biyem-Assi, and the
District Hospital of Cité Verte). In Mali, thanks to the previous
creation of diabetes registries derived from diabetes-clinic records,
the recruitment pool included all persons with diagnosed diabetes
living in or near the country’s three largest cities: Bamako, the
national capital, population 1.8 million, Sikasso, population
130,000, and Tombuctou, population 58,000. Cases were
probability-sampled in Bamako and sampled exhaustively in
Siskasso and Tombuctou. In Tanzania, cases were selected
randomly from a diabetes registry created from health facility
records in Temeke, population 800,000, one of the three local
government areas within the capital province, Dar es Salaam. In
South Africa, cases were identified consecutively from the waiting
room of the diabetes clinic at Mamelodi Hospital serving
Mamelodi, a predominantly black township east of Pretoria
(Tshwane Metropolitan area).
Once cases were identified and agreed to participate, eachcase
was asked to identify five persons of the same sex and approximate
age living closest to them. We then contacted and recruited one
control subject for each case using this information. Potential
controls who said they had been diagnosed with diabetes were
excluded.
The Interview
The 25-page interview questionnaire (Appendix A) was
developed initially in English, translated into French, and then
back-translated into English to perfect the translation. The
medical utilization questions analyzed in the present paper were
adapted to fit African circumstances from previously validated
survey items. [17–18] and tested in two languages, English and
French. English versions were field-tested in Kenya and Tanzania
and French versions were field-tested in Mali until a final
questionnaire, identical in all respects except language, was
accepted. Interviewers were medical professionals who were
trained and performed practice interviews prior to entering the
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field. In Tanzania, interviewers orally translated the questionnaire
into Kiswahili when subjects were not fluent in English.
The interview included questions about: the participant’s use of
allopathic and traditional medical services over the previous 90
days; payments made at the time of service for medical care
services; medicines currently in the participant’s possession; the
use, price, and sources of these medicines; the subject’s receipt of
essential diabetes-related medical care, the subject’s diabetes-self-
care practices, and health-related quality of life. All interviews
were conducted by physicians or field workers who had been
trained in a central location in each country. Prior to starting the
interview, interviewers confirmed and recorded each subject’s
informed voluntary consent to participate. Most of the interviews
were completed in 2008 and occurred in the subjects’ homes.
Data Entry and Verification
Interview answers were recorded on a paper form (Appendix A)
and subsequently entered electronically by each study team using
one of two data entry programs, one web-based and one personal
computer-based, that the coordinating center developed in
collaboration with the national study teams. The reliability of
both data entry programs was verified by entering the entirety of
the Tanzanian data using both methods and comparing the results
both across programs and against the hard-copy records. In
addition, countries using the interactive program were given
spreadsheet copies of their data, which they then compared and
corrected as necessary against their hard-copy records. Finally,
prior to analysis, the coordinating center scoured every variable in
each country’s database for data that were out of range or
inconsistent with other variables. Suspect values were then re-
checked against the hard-copy records by the national study teams
and excluded from the analysis dataset if a correct response could
not be found in the hard-copy interview form. Prior to substantive
data analysis, we reduced two extreme outlier values to the level of
the next-largest unmodified value. Also prior to analysis, to
prevent bias arising from rare and uncharacteristically long
hospital stays, we Winsorized [19–20] the hospitalization data by
reducing two extreme outlier values for hospital days to the level of
the next-largest unmodified value in the dataset.
Estimation of Annual Use of Medical Care
As described, the study team relied on participant recall to
ascertain use of medical care services. To increase accuracy, we
limited recall to a 90-day window and, to calibrate the window,
asked respondents to name and associate a well-remembered event
that had occurred approximately 90 days previously. To learn
about the use of medicines, interviewers asked subjects to show
them the medicines they were using and to tell them about their
most recent purchase of each medicine. To further increase
accuracy, and to control respondent burden, we asked for details
only about the most recent hospital outpatient visit, overnight
hospitalization, and purchase of each medicine. The study team
then used the descriptions of this subset of most-recent events to
estimate the characteristics of all events of the same kind, such as
reasons for admissions and visits and mean length of hospital stay.
Annual rates of use of outpatient medical services were
calculated by multiplying the amounts self-reported for the
preceding 90 days by 4.0. [12] Although participants were asked
about visits to hospital emergency wards, too few such visits were
reported to support analysis, probably because emergency room
visits were defined to exclude emergency-ward visits that resulted
in an overnight stay. We excluded data on emergency-ward visits
from this report. To estimate the last 90 days and annual number
of medicines taken we used the self-reported number of pills per
day and number of days per week these medicines were reported
to be frequently taken. The recall window for hospitalisations was
365 days.
Hypotheses and Hypothesis Testing
The study team’s a priori primary hypotheses were that total
per-person hospital admissions, inpatient days, outpatient visits,
and purchases of medicines by persons with DM would exceed
total per-person use by matched controls (MCs), after adjustment
for any residual differences in age and sex that were not directly
controlled by matching. These hypotheses could not be tested
using one-stage statistical procedures because most subjects had
had no admissions during the last 90 days, a few had no outpatient
visits, and some were taking no medicines when interviewed.
Therefore, we used two-stage ‘‘hurdle’’ models [21] to test for
differences in total service utilization. In the first stage, we used
multivariable logistic regression models that included age, sex, and
case status (DM = 1, MC = 0) to test for differences in the
proportion of subjects with a non-zero value on the utilization
event of interest, e.g., persons with at least one overnight
admission or outpatient visit (OPV) during the preceding 90 days,
or at least one current medicine (analysis done only among persons
who reported use of at least one type of medical services). Then,
we estimated a second-stage multivariable model using the same
independent variables on a dataset containing only the observa-
tions with non-zero values. The functional form of the second-
stage model depended on the underlying distribution of values: for
counts of admissions, OPVs, and medicines, a Poisson model was
used, while for total days in hospital, i.e., cumulative length of stay
among having at least one hospital admission (if admitted), we
checked for approximate normality and used ordinary least
squares (OLS). Models were estimated using the free and open-
source R program, which did not yield a single overall confidence
interval for both stages simultaneously. However, if the coefficient
on DM status is positive and significantly different from zero in the
first model, and not significantly negative in the second model,
then the two models together may be considered to confirm a
utilization-increasing effect of diabetes. Because our primary
hypotheses were one-sided, we used one-sided tests of significance.
We considered but decided not to use random-effects models
because our study locations were not intended to approximate a
random sample of their respective countries or of Africa. For the
same reason, we omitted site from our statistical models. (We
evaluate the representativeness of our sites and subjects in the
Discussion section).
Tabulation of Healthcare Use
The absolute amount of medical care associated with, and
arguably caused by diabetes can be estimated by subtracting
results for matched comparison subjects from results for persons
with DM. However, for comparison to other studies conducted at
other places and times, a more robust statistic is the adjusted ratio
of medical service use among persons with DM to the medical
service use by MCs (DM:MC ratio). Ratios are much less
influenced than absolute differences by variations in source data,
recruitment methods, and differences in health systems and
patterns of medical practice [3,22–24].
Results
Usable data were obtained on 1780 cases with diagnosed
diabetes and 1770 matched controls. The mean age of DMs was
54.8 years; 64.7 percent of DMs were women. MCs were very
similar to DMs, with mean age 53.7 and 65.0 percent women
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(Table 1). Subjects were older in South Africa (mean age 61.0 and
60.5 for DMs and MCs, respectively) and more likely to be female
in Mali and South Africa. Although cases and comparison subjects
were not directly matched on family income, we observed similar
self-reported annual family incomes per capita, averaging USD
2570 for DMs and USD 2280 for comparators. Family income
varied by country: it was lowest in Tanzania (DM: USD 1231) and
highest in Cameroon (DM: USD 3917). In all countries, family
size, defined as ‘‘the number of people who normally eat with you
where you live,’’ was slightly larger among DMs than among MCs,
8.6 vs. 7.7. In Mali, family size was particularly large by our
definition because extended families usually dine together in that
country (15.7 for DMs and 13.9 for MCs). DMs and MCs were
very similar in educational attainment, with 25.2% and 24.3%
reporting no formal schooling, respectively, although highest level
of schooling completed varied widely by country, with 47.0% and
26.6% of DMs reporting no formal schooling in Mali and
Tanzania, respectively; by contrast, 14.4% of the DMs in
Cameroon had attended university, compared to 1.0% or fewer
in the other three countries.
Use of Inpatient Care
As shown in Table 2, the rate of admissions per person was
0.049 among persons with DM during the preceding 90 days,
compared to 0.011 among matched comparison subjects. After
accounting for multiple admissions each person in the study group
with diabetes averaged 0.28 admissions per person per year,
compared to 0.045 admissions per year for MCs, a 6.63-fold
difference. Because MCs reported so few hospital admissions, we
were unable to tabulate age-group-specific differences or ratios in
admission rates or duration of inpatient stay by age-group.
The first stage of the hurdle model confirmed that persons with
DM were more likely to have had at least one admission than
persons with MC after indirect multivariable adjustment for age
and sex (p,0.01). In the second stage of the hurdle model, the
mean number of admissions per person, if admitted during the
preceding 90 days, was also higher in persons with DM (p,0.01)
in a multivariable zero-truncated Poisson count model. Thus, the
hypothesis that DMs experienced more admissions than MCs was
confirmed.
Hospital stays were about twice as long for persons with DM
(12.15 days) than for MCs (5.88 days, data not shown), so total
annual inpatient days per person were 12.95 times higher among
DMs (3.44 inpatient days per person per year for DMs versus 0.27
inpatient days per person per year for MCs). As presented in
Table 2, among persons with DM in the study sample, annual
inpatient admissions and especially annual inpatient days per
person increased with age and formed a U-shaped pattern as a
function of increasing self-reported time since diagnosis. The
second stage of the hurdle process confirmed that total hospital
days were higher for DMs than for MCs (p,0.01).
Use of Outpatient Care
Table 3 displays the self-reported use of outpatient services by
diabetes status, age, sex and four groups of diabetes duration. Over
90 percent of DMs (90.5%) reported having at least one outpatient
in the last 90 days. The 90-day average for total visits, among DMs
with at least one visit, was 2.8. By comparison, only 15.4 percent of
MCs reported at least one visit during the previous 90 days and
they reported 1.72 visits over the period if they had had at least
one visit. Excluding visits to traditional healers, nearly all (10.3 out
of 10.7) OPVs by DMs were to hospital-based clinicians (doctors
or nurses). Relative to their use of allopathic OPVs, MCs used
traditional healers frequently, 1.04 visits out of 2.73 total visits per
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year (38.1%). DMs averaged slightly more annual visits to
traditional healers, 1.37, but traditional healers accounted for a
much lower proportion of total DM OPVs (11.3% of 12.09 total
visits per year).
Overall, not counting visits to traditional healers, persons with
diabetes reported 7.54 times more ambulatory medical encounters
per year than matched subjects who did not have diabetes. Among
DMs, visits per year did not vary significantly by age or by
duration of diagnosed diabetes. Older MCs reported more OPVs
per year than younger MCs.
With respect to the formal hypothesis that persons with DM
used more OPVs than MCs, the coefficient on diabetes was
statistically significant (p,0.01) in a positive direction in both the
first-stage, zero hurdle logistic model and in the second-stage
Poisson-regression count model, confirming the a priori hypoth-
esis.
Our study-wide averages conceal considerable variation among
the four countries. Total annual allopathic OPVs for DMs were
much higher in Cameroon (13.41) and Mali (14.09) than in South
Africa (5.54) and Tanzania (7.73), data not shown. DMs in
Cameroon and especially in Mali were much more likely to use
traditional healers than DMs in South Africa and Tanzania
(Cameroon and Mali: 0.97 and 3.74 visits/year, respectively;
South Africa and Tanzania: less than 0.01 and 0.049 visits/year,
respectively).
Table 4 shows the causes of hospital admissions and hospital
outpatient visits, as reported by the subjects. Half (49.6%) of the
hospital admissions of DMs were attributed to ‘‘diabetes’’ rather
than to any particular diabetic complication, such as heart disease
(5.6%) or stroke (0.8%). MCs attributed 38.9% of their admissions
to ‘‘other,’’ and recalled very few admissions for problems that can
be caused by diabetes. DMs attributed fully 95.1% of their most
recent hospital outpatient visits to ‘‘diabetes,’’ while MC attributed
73.0% of their visits to ‘‘other’’.
Use of Medicines
Table 5 summarizes the use of medicines by DMs and MCs.
Nearly all cases with DM (94.8%) possessed and reported taking at
least one medicine at the time they were interviewed, compared to
one-fourth (26.7%) of matched controls. DMs who were using a
medicine also used more medicines in total than MCs who were
using a medicine (2.60 vs. 1.60 medicines per person). The mean
number of medicines used per person with DM in the study (2.49)
was 5.61 times greater than the mean number of medicines used
by MCs (0.44). The DM vs. MC difference in use of any medicine
was highly statistically significant (p,0.01) in the first-stage logistic
model; in the second-stage Poisson model, the mean number of
medicines among persons taking any medicine was also signifi-
cantly higher for DMs (p,0.01). The combination of these two
results confirms the study hypothesis for medicine use.
Unlike annual outpatient visits per person, medicines used per
person increased with age and with the length of time since
diagnosis among DMs (both p,0.01) and, for MCs, increased with
age (p,0.05). As presented in Table 6, except in Tanzania, DMs
purchased three-fifths to three-quarters of their medicines from
public hospital pharmacies. In Tanzania, DMs bought 84.4% of
medicines from private pharmacies.
Discussion
We interviewed samples of persons with diagnosed diabetes and
age-, sex-, and residence-matched comparison subjects without
diagnosed diabetes in Cameroon, Mali, South Africa and
Tanzania. We found that the use of medical services and
medicines was dramatically higher among DMs than among
MCs. DMs used 6.27 times more inpatient admissions, 12.95 times
more days of inpatient treatment, 7.54 times more outpatient
visits, and 5.61 times more prescription medications. DMs used an
estimated 3.44 inpatient days per person per year, made 10.72
outpatient visits per person per year (excluding traditional healers),
and were taking a average of 2.49 prescribed medicines when
interviewed. These ratios are much higher than recently published
ratios for similar comparisons in developed countries (average 2.0–
2.4 for total medical expenditures) [25–26] and much higher than
the ratios observed in a companion study using a similar interview
schedule and case-control design in China, where the medical
services use ratios of DMs relative to subjects with normal glucose
tolerance (NGT) were 1.93 for inpatient days, 2.40 for outpatient
visits, and 3.35 for medicines [12].
A number of factors combine to explain why persons with
diagnosed diabetes in our study used so many more medical
services. One important factor is that, unlike much of the
industrialized world in recent years, and unlike our companion
study in China that ascertained diabetes by population-based
household screening, a majority of diabetes cases in Africa remain
Table 6. Sources of medicines (%).
Private Pharmacy Hospital Pharmacy
Site
CAMEROON
Yaoundé 42.2 57.8
MALI
Bamako 35.6 64.4
Sikasso 42.3 57.7
Tombouctou 26.3 73.7
All Sites 36.7 63.3
TANZANIA
Temeke (Dar es Salaam) 84.4 16.6
SOUTH AFRICA
Mamelodi (Tshwane) 25.0 74.5
doi:10.1371/journal.pone.0106716.t006
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undiagnosed. [27] In Africa, testing for diabetes usually occurs
after patients present with complications known to arise from
diabetes. [27] This means that, as a group, persons recognized as
having diabetes in Africa (and in other LMICs) are much sicker
than their counterparts in many other places, and need more
services and medications.
A second major cause of the high relative cost of diabetes care in
Africa–and another reasons why Africans diagnosed with diabetes
are much sicker–is that Africans with diabetes are not given
inexpensive basic medicines to control hypertension and dyslipi-
demia, and also probably do not have good blood sugar control.
[14] This results in expensive, disabling complications, [28–32]
which greatly increase the need for medical services [33–35].
In this connection, we note that in other data from our study, a
high portion of medical care costs in Africa are incurred by
patients, not covered by insurance, government or charity. As
shown in Table 7, to pay their medical expenses many families
must use their savings, borrow from friends and relatives, or sell
their assets. DMs were over four times more likely than MCs to
report selling possessions, houses or land to raise funds to pay for
medical care (Table 7). As a result, people with diabetes may not
seek required preventive care, increasing the risk of complications,
which are more cost yet (if treated).
Our African subjects with diabetes did not use more hospital-
izations or visits or pills than DMs in China or Europe or North
America [22–26] but our subjects without diabetes used very few
medicines and services relative to other countries. This underuse
of medical care by the general population is a third driver of the
large diabetes-associated differences that we report. Medical care
in Africa is very costly relative to mean family income, difficult and
time-consuming to access, and often unrewarding [27].
The present study has features and limitations that should be
kept in mind when using and interpreting its results. First, as just
described, our study samples excluded undiagnosed cases.
Therefore, our reported differences and ratios probably overesti-
mate medical services utilization per person among persons with
undiagnosed diabetes. Second, as it is neither possible nor
desirable to assign diabetes experimentally, our research design
was observational. However, our case-control design is now the
most widely used and accepted approach for measuring the
economic and social impacts of diabetes, [22–26] for two reasons:
(a) the effects and complications of diabetes are so numerous and
serious that it is valid to assume that diabetes is the cause of the
great majority of the events that are observationally associated
with it, once the strong effects of age, sex, and socio-economic
status (including three indicators: income, occupation and
education) are controlled; and (b) diabetes complications are often
not recognized as related to diabetes by caregivers and patients,
which rules out bottom-up, medical record- or patient-based
counting designs. [24] Our matching procedure appeared to
succeed very well; not only were age and sex very similar across
our DM and MCs, as would be expected, but DMs and MCs were
also similar on family income per person and educational
attainment, variables on which we did not match directly.
The communities we sampled were not entirely representative
of their countries. In Mali, all the known persons with diabetes
were randomly or exhaustively sampled in the three largest cities,
but rural residents were excluded. In Cameroon, the sample
largely consisted of consecutive users of the outpatient clinics of the
university hospital in the capital city, a procedure that probably
over-selected DMs who were more ill and more likely to use–and
more likely to be able to afford–services. The Tanzanian sample
was representative of all diagnosed residents of Temeke, a major
suburban area of the capital province, but excluded both
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downtown Dar es Salaam and the interior of Tanzania. Compared
to World Bank estimates of mean national income per capita for
2008, [36] when most of our interviews were conducted, mean
incomes per family member among our DMs and MCs,
respectively, were 3.4 and 2.6 times higher than the national
average in Cameroon, 5.6 and 5.0 times higher in Mali, and 5.1
and 4.5 times higher in Tanzania. In South Africa, our sample
contained almost exclusively black residents of a former segregated
black township. Blacks comprise 79% of the South African
population, [37] so our sample resembles the majority of South
Africans racially. However, mean income per family member in
our diabetes sample was still about 2.1 times higher than mean
national income for black South Africans [38].
Fortunately, these large differences in relative affluence do not
necessarily imply that our estimate of the absolute and relative
impact of diabetes misrepresent Africans as a whole. Although
urban Africans earn more income than rural Africans, they are
also two to four times as likely to develop diabetes, [39–42] and
higher-income residents of LMICs are two to three times more
likely to develop diabetes, regardless of where they live. [43]
Therefore, had we had the resources to undertake a fully
population-based probablility sampling of Africans with diabetes,
the resulting study subjects with diabetes would still have been
predominantly urban and higher-income and–equally important-
ly–the control subjects without diabetes would have been much
more rural and lower-income. As a consequence, we would have
calculated much larger differences in medical care use than we
have reported, because our matched control subjects undoubtedly
used more medical services than similarly aged men and women in
rural areas.
A final consideration in interpreting our results is that all our
utilization data were obtained from patients’ self-reports. An
extensive literature, albeit from industrialized countries, suggests
that patients can recall the occurrence and many details of medical
care encounters for up to three months, and recall the occurrence
if not the details of hospitalizations for at least one year. [44–48]
To the extent that patient recall fails, it usually fails in the direction
of under-reporting, especially of outpatient visits. [47,48] Under-
reporting also increases with the number of encounters during the
recall period. In this study, we minimized under-reporting by
limiting counts of both visits and hospitalizations to a 90-day
window and asking about the details of visits and hospitalizations
for only the most recent encounter within that window. Any
under-reporting in our data should have the effect of downwardly
biasing our estimates of the effects of diabetes on medical care use,
because subjects with diabetes had so many more encounters than
controls. Note that, for medication use, we did not rely on recall
but instead asked subjects to physically show us the medicines they
were currently taking.
In view of the remarkably and unexpectedly large absolute and
relative magnitude of additional medical care use that we observed
to be associated with a diabetes diagnosis, there can be no doubt
that diabetes imposes a huge burden on families and medical care
systems in most, if not all Sub-Saharan African countries. The best
previous estimates of the expenditures for medical care caused by
diabetes assume a DM/MC ratio of 2.0. [2] Our results show that
expenditure ratios for Sub-Saharan African countries and perhaps
other LMICs are actually much higher. African governments have
a strong economic incentive to prevent expensive diabetic
complications through earlier diagnosis and effective, low-cost
preventive treatment.
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